Table 2.

Summary efficacy analysis

Group	PR	CR	SD	PD	Median PFS (months)	95% CI	6-month PFS* (%)
Full cohort (N=37)†	13	0	21	3	13.7	10.8, 16.4	78
Unclassified, papillary features (N=23)	10	0	12	1	13.7	10.8, 19.2	82
Papillary (N=13)	3	0	8	2	8.4	3.2, 16.4	68
Translocation, papillary features (N=1)	0	0	1	0	-	-	100

Abbreviations: CR, complete response; NA, not applicable; NR, not reached; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease.

^*Kaplan-Meier estimates

^†Radiographic response assessment not performed for 2 patients: 1 with uRCC with papillary features contributed to PFS but not the overall response rate (ORR) due to clinical progression but lack of radiographic evaluation on study; the other with pRCC was removed from the study after one bevacizumab dose due to post-enrollment safety concerns and did not contribute to ORR or PFS analyses.